Cullgen
Targeted protein degradation technology for next-generation therapeutics
- Headquarters
- San Diego, California
- Employees
- 11–50
- Business Model
- B2B
- Website
- cullgen.com
About
Cullgen is a clinical-stage biopharmaceutical company dedicated to developing first-in-class medicines using its proprietary targeted protein degradation (TPD) technology platform. The company develops small molecule targeted protein degraders and degrader antibody conjugates (DACs) that recruit the body's natural protein disposal system to eliminate disease-causing proteins, targeting diseases that lack effective therapeutic approaches. Cullgen raised $40 million in 2023 led by AstraZeneca and CICC Fund, and entered a definitive agreement to be acquired by Gyre Therapeutics in March 2026.
Summary
Cullgen is a Biotech company based in San Diego, United States.
Tech & App Stack
1 technologies & apps tracked
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company